Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models

Yoshinori Kato, Baasil Okollie, Venu Raman, Farhad Vesuna, Ming Zhao, Sharyn D. Baker, Zaver M Bhujwalla, Dmitri Artemov

Research output: Contribution to journalArticle

Abstract

Vasculature mediated drug resistance in tumors was studied in female SCID mice bearing wild type MCF-7 and adriamycin resistant MCF-7/ADR xenograft using temozolomide (TMZ). A strong tumor growth inhibitory effect of TMZ treatment was observed in MCF-7 tumors during the initial treatment phase with subsequent relapse, but not in MCF-7/ADR tumors. Non-invasive MRI measurements of tumor vascular volume and vascular permeability-surface area product (PS) demonstrated significant reduction of PS in long-term treated MCF-7, but not in MCF-7/ADR tumors. O6-Methylguanine-DNA methyltransferase (MGMT) mRNA, and VEGF expression was analyzed using real-time RT-PCR and ELISA, respectively. No significant changes in MGMT mRNA and VEGF expression were observed in either MCF-7 or MCF-7/ADR tumors. However, in vitro incubation of MCF-7 cells with TMZ did induce the expression of MGMT mRNA. In addition, p53 and p21 levels were scored by immunoblotting. Exposure of cells to TMZ did not affect either the p21 or the p53 expression in both MCF-7 and MCF-7/ADR cells. The absence of these molecular responses to TMZ treatment in MCF-7 tumors in vivo supports the possibility that the onset of cancer drug resistance is associated with reduced PS, which can decrease delivery of the drug to cancer cells.

Original languageEnglish (US)
Pages (from-to)891-897
Number of pages7
JournalCancer Biology and Therapy
Volume6
Issue number6
StatePublished - Jun 2007

Fingerprint

temozolomide
R Factors
Heterografts
Neoplasms
Methyltransferases
MCF-7 Cells
Drug Resistance
Messenger RNA
Vascular Endothelial Growth Factor A
DNA
SCID Mice
Capillary Permeability
Tumor Burden

Keywords

  • Breast cancer
  • Chemotherapy
  • Drug resistance
  • MCF-7
  • MCF-7/ADR
  • Temozolomide
  • Tumor vascular function

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. / Kato, Yoshinori; Okollie, Baasil; Raman, Venu; Vesuna, Farhad; Zhao, Ming; Baker, Sharyn D.; Bhujwalla, Zaver M; Artemov, Dmitri.

In: Cancer Biology and Therapy, Vol. 6, No. 6, 06.2007, p. 891-897.

Research output: Contribution to journalArticle

@article{daa3ecc60f48461c9d1dd1635e61d439,
title = "Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models",
abstract = "Vasculature mediated drug resistance in tumors was studied in female SCID mice bearing wild type MCF-7 and adriamycin resistant MCF-7/ADR xenograft using temozolomide (TMZ). A strong tumor growth inhibitory effect of TMZ treatment was observed in MCF-7 tumors during the initial treatment phase with subsequent relapse, but not in MCF-7/ADR tumors. Non-invasive MRI measurements of tumor vascular volume and vascular permeability-surface area product (PS) demonstrated significant reduction of PS in long-term treated MCF-7, but not in MCF-7/ADR tumors. O6-Methylguanine-DNA methyltransferase (MGMT) mRNA, and VEGF expression was analyzed using real-time RT-PCR and ELISA, respectively. No significant changes in MGMT mRNA and VEGF expression were observed in either MCF-7 or MCF-7/ADR tumors. However, in vitro incubation of MCF-7 cells with TMZ did induce the expression of MGMT mRNA. In addition, p53 and p21 levels were scored by immunoblotting. Exposure of cells to TMZ did not affect either the p21 or the p53 expression in both MCF-7 and MCF-7/ADR cells. The absence of these molecular responses to TMZ treatment in MCF-7 tumors in vivo supports the possibility that the onset of cancer drug resistance is associated with reduced PS, which can decrease delivery of the drug to cancer cells.",
keywords = "Breast cancer, Chemotherapy, Drug resistance, MCF-7, MCF-7/ADR, Temozolomide, Tumor vascular function",
author = "Yoshinori Kato and Baasil Okollie and Venu Raman and Farhad Vesuna and Ming Zhao and Baker, {Sharyn D.} and Bhujwalla, {Zaver M} and Dmitri Artemov",
year = "2007",
month = "6",
language = "English (US)",
volume = "6",
pages = "891--897",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models

AU - Kato, Yoshinori

AU - Okollie, Baasil

AU - Raman, Venu

AU - Vesuna, Farhad

AU - Zhao, Ming

AU - Baker, Sharyn D.

AU - Bhujwalla, Zaver M

AU - Artemov, Dmitri

PY - 2007/6

Y1 - 2007/6

N2 - Vasculature mediated drug resistance in tumors was studied in female SCID mice bearing wild type MCF-7 and adriamycin resistant MCF-7/ADR xenograft using temozolomide (TMZ). A strong tumor growth inhibitory effect of TMZ treatment was observed in MCF-7 tumors during the initial treatment phase with subsequent relapse, but not in MCF-7/ADR tumors. Non-invasive MRI measurements of tumor vascular volume and vascular permeability-surface area product (PS) demonstrated significant reduction of PS in long-term treated MCF-7, but not in MCF-7/ADR tumors. O6-Methylguanine-DNA methyltransferase (MGMT) mRNA, and VEGF expression was analyzed using real-time RT-PCR and ELISA, respectively. No significant changes in MGMT mRNA and VEGF expression were observed in either MCF-7 or MCF-7/ADR tumors. However, in vitro incubation of MCF-7 cells with TMZ did induce the expression of MGMT mRNA. In addition, p53 and p21 levels were scored by immunoblotting. Exposure of cells to TMZ did not affect either the p21 or the p53 expression in both MCF-7 and MCF-7/ADR cells. The absence of these molecular responses to TMZ treatment in MCF-7 tumors in vivo supports the possibility that the onset of cancer drug resistance is associated with reduced PS, which can decrease delivery of the drug to cancer cells.

AB - Vasculature mediated drug resistance in tumors was studied in female SCID mice bearing wild type MCF-7 and adriamycin resistant MCF-7/ADR xenograft using temozolomide (TMZ). A strong tumor growth inhibitory effect of TMZ treatment was observed in MCF-7 tumors during the initial treatment phase with subsequent relapse, but not in MCF-7/ADR tumors. Non-invasive MRI measurements of tumor vascular volume and vascular permeability-surface area product (PS) demonstrated significant reduction of PS in long-term treated MCF-7, but not in MCF-7/ADR tumors. O6-Methylguanine-DNA methyltransferase (MGMT) mRNA, and VEGF expression was analyzed using real-time RT-PCR and ELISA, respectively. No significant changes in MGMT mRNA and VEGF expression were observed in either MCF-7 or MCF-7/ADR tumors. However, in vitro incubation of MCF-7 cells with TMZ did induce the expression of MGMT mRNA. In addition, p53 and p21 levels were scored by immunoblotting. Exposure of cells to TMZ did not affect either the p21 or the p53 expression in both MCF-7 and MCF-7/ADR cells. The absence of these molecular responses to TMZ treatment in MCF-7 tumors in vivo supports the possibility that the onset of cancer drug resistance is associated with reduced PS, which can decrease delivery of the drug to cancer cells.

KW - Breast cancer

KW - Chemotherapy

KW - Drug resistance

KW - MCF-7

KW - MCF-7/ADR

KW - Temozolomide

KW - Tumor vascular function

UR - http://www.scopus.com/inward/record.url?scp=42449156775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449156775&partnerID=8YFLogxK

M3 - Article

C2 - 17582214

AN - SCOPUS:42449156775

VL - 6

SP - 891

EP - 897

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 6

ER -